

Developing an ED-Initiated Buprenorphine Program

Kathryn Hawk, MD, MHS

Gail D'Onofrio, MD

Department of Emergency Medicine

Yale University School of Medicine



Disclosure Statement

Current grant funding:



Provided funding for filming & production of videos displayed on our interactive web portal



**The 24/7/365-day Option
To Fight the Opioid
Crisis**



Why focus on the ED?

Because that's where the patients are




Overdose



Seeking Treatment

Screening



EDs and Emergency Physicians can...

- Identify patients with OUD
- Provide treatment
 - Initiate buprenorphine
 - Overdose education and naloxone distribution
- Directly link patient to continued opioid agonist therapy & preventive services



A Randomized Trial of ED-Initiated Interventions for Opioid Dependence

Research

D'Onofrio, G., O'Connor, P.G., Pantalon, M.V., Chawarski, M.C., Busch, S.H., Owens, P.H., Bernstein, S.L. and Fiellin, D.A.

Original Investigation

Emergency Department–Initiated Buprenorphine/Naloxone Treatment for Opioid Dependence A Randomized Clinical Trial

Gail D'Onofrio, MD, MS; Patrick G. O'Connor, MD, MPH; Michael V. Pantalon, PhD; Marek C. Chawarski, PhD; Susan H. Busch, PhD; Patricia H. Owens, MS; Steven L. Bernstein, MD; David A. Fiellin, MD

IMPORTANCE Opioid-dependent patients often use the emergency department (ED) for medical care.

OBJECTIVE To test the efficacy of 3 interventions for opioid dependence: (1) screening and referral to treatment (referral); (2) screening, brief intervention, and facilitated referral to community-based treatment services (brief intervention); and (3) screening, brief intervention, ED-initiated treatment with buprenorphine/naloxone, and referral to primary care for 10-week follow-up (buprenorphine).

DESIGN, SETTING, AND PARTICIPANTS A randomized clinical trial involving 329 opioid-dependent patients who were treated at an urban teaching hospital ED from April 7, 2009, through June 25, 2013.

INTERVENTIONS After screening, 104 patients were randomized to the referral group, 111 to

+ JAMA Report Video and Author Video Interview at jama.com


+ CME Quiz at jamanetworkcme.com
CME Questions p



NIDA 5R01DA025991

JAMA. 2015;313(16):1636-1644.

ED-Bup: 2x More Likely to be Engaged in Addiction Treatment at 30 Days



Translating Research into Practice



Resources

<https://www.drugabuse.gov/ed-buprenorphine>

Why the Emergency Department (ED)?

That is Where the Patients

Are! The opioid epidemic is strongly impacting EDs, with 2018 data from the CDC indicating that there has been a 30% increase in visits for opioid overdose from July 2016 –

September 2017¹. Addiction is a chronic, relapsing disease, and strongly stigmatized one. **It is NOT a moral failing.** People who present to the ED for other chronic disease like diabetes and asthma are stabilized with medications and handed off for outpatient care. Individuals with opioid use disorder (OUD) do so with a similar treatment plan.


What is the Evidence?

A 2015 study (JAMA) found that twice as many patients were in OUD treatment at 30 days (~80%) with ED-initiated buprenorphine & a brief negotiation interview (BNI) compared to referral only or a BNI + facilitated referral and used less illicit opioids in the last 7 days.²

What Do I Need to Know About Buprenorphine?

It is NOT simply replacing one drug for another.

Buprenorphine treatment decreases withdrawal and craving



Facts for Medication

KEY DOCUMENTS

- Buprenorphine Algorithm
- Identification of OUD based on DSM-5
- Clinical Opioid Withdrawal Scale (COWS)
- Buprenorphine Referral Form
- Home Buprenorphine Initiation

RESEARCH UPDATES

ONLY THREE IN TEN PEOPLE WHO SURVIVE AN OVERDOSE RECEIVE MEDICATION TREATMENT

The researchers identified 17,568 cases where an adult in Massachusetts survived an overdose between 2012 and 2014. There was a 59% reduction in mortality for individuals taking methadone compared to those not taking medication, and a 38% reduction in mortality for those treated with buprenorphine. There was no change in mortality associated with naltrexone. Despite these gains relative to morbidity, in the 12 months following the OD, only 34% of individuals received any medication for OUD: 11% received methadone maintenance treatment (median of 5 months); 17 received buprenorphine (median of 4 months); 6% received naltrexone (median of 1 month).

Treatment with opioid agonist therapy (methadone and buprenorphine) is associated with a reduction in all-cause and opioid-related mortality. Only a minority of overdose survivors received treatment.

Larochelle et al., Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality. Annals Of Internal Med, 2018.

<https://medicine.yale.edu/edbup/>

ED-Initiated Buprenorphine

The Yale Department of Emergency Medicine is pleased to provide this website as a comprehensive resource for any provider seeking information on ED-initiated buprenorphine. Please check back often as we will be continuously updating the materials provided here.



Overview

[Read More](#)



Assessments & Tools

[Read More](#)



Treatment: Buprenorphine Algorithm & BNI


[Read More](#)




Discharge and Treatment Referral

[Read More](#)


**How do I start
buprenorphine in the ED?**





"I THINK YOU SHOULD BE MORE EXPLICIT HERE IN STEP TWO."

Buprenorphine Integration Pathway



- ① Formally assess for opioid use disorder**
- ② Formally assess the severity of opioid withdrawal (COWS)**
- ③ Assess patient willingness for BUP**
- ④ Provide ED-initiated buprenorphine (ED or home induction)**
- ⑤ Overdose education and naloxone distribution (OEND)**
- ⑥ Provide formal referral for ongoing opioid agonist treatment**

DSM-5 criteria for diagnosis of Opioid Use Disorder

At least 2 criteria must be met within a 12 month period

1. Take more/longer than intended
2. Desire/unsuccessful efforts to quit opioid use
3. A great deal of time taken by activities involved in use
4. Craving, or a strong desire to use opioids
5. Recurrent opioid use resulting in failure to fulfill major role obligations
6. Continued use despite having persistent social problems
7. Important activities are given up because of use.
8. Recurrent opioid use in situations in which it is physically hazardous (e.g. driving)
9. Use despite knowledge of problems
10. Tolerance
11. Withdrawal

Severity

Presence of Symptoms

Mild: 2-3

Moderate: 4-5

Severe: ≥ 6

- ① **Formally assess for opioid use disorder**
- ② **Formally assess the severity of opioid withdrawal (COWS)**
- ① **Assess patient willingness for buprenorphine**
- ① **Provide ED-initiated buprenorphine (ED or home induction)**
- ② **Overdose education and naloxone distribution (OEND)**
- ③ **Provide formal referral for ongoing opioid agonist treatment**

COWS

3,



The picture can't be displayed.

3,



The picture can't be displayed.

Score:

5-12= Mild

13-24= Moderate

25-36= Moderately Severe

- ① **Formally assess for opioid use disorder**
- ② **Formally assess the severity of opioid withdrawal (COWS)**
- ③ **Assess patient willingness for buprenorphine**
- ④ **Provide ED-initiated buprenorphine (ED or home induction)**
- ⑤ **Overdose education and naloxone distribution (OEND)**
- ⑥ **Provide formal referral for ongoing medication assisted treatment**

Anyone Can Treat Opioid Withdrawal with Buprenorphine

2.



The picture can't be displayed.

72-hour rule

Title 21, Code of Federal Regulations, Part 1306.07(b)


Allows to administer (but not prescribe) narcotic drugs for the purpose of relieving acute withdrawal symptoms while arranging for the patient's referral for treatment

- **Not more than 1-day's medication may be administered or given to a patient at one time**
- **Patient must return to ED each day for no more than 72 hours**
- **This 72-hour period cannot be renewed or extended.**




How do you motivate patients
to accept treatment?


What makes people take action?




Autonomy
(freedom)



Engaging
Talk



Hearing
Themselves



Making a
Plan

3,



The picture can't be displayed.

3,



The picture can't be displayed.

People only really listen to
1 person...

THEMSELVES!

Yale SCHOOL OF MEDICINE



Yale SCHOOL OF MEDICINE




- ① Formally assess for opioid use disorder**
- ② Formally assess the severity of opioid withdrawal (COWS)**
- ③ Assess patient willingness for buprenorphine**
- ④ Provide ED-initiated buprenorphine (ED or home induction)**
- ⑤ Overdose education and naloxone distribution (OEND)**
- ⑥ Provide formal referral for ongoing medication assisted treatment**

3,



The picture can't be displayed.

Algorithm

 The picture can't be displayed.

- ① **Formally assess for opioid use disorder**
- ② **Formally assess the severity of opioid withdrawal (COWS)**
- ③ **Assess patient willingness for buprenorphine**
- ④ **Provide ED-initiated buprenorphine (ED or home induction)**
- ⑤ **Overdose education and naloxone distribution (OEND)**
- ⑥ **Provide formal referral for ongoing opioid agonist treatment**


Those at Highest Risk for Overdose

- Prior non-fatal opioid overdose
- Opioid use disorder leaving controlled settings (e.g. residential treatments, detoxification, incarceration) who have lowered opioid tolerance
- Prescribed doses of opioid analgesics greater than 90 milligram morphine equivalents (MME) per day
- Taking (co-prescription or co-use) opioids and benzodiazepines
- Alcohol and opioids
- Injecting opioids
- Exposed to high potency opioids (fentanyl, W-18)
- Low levels of physical tolerance (new initiates)
- Sleep disordered breathing (e.g. sleep apnea)

Yale SCHOOL OF MEDICINE



- ① Formally assess for opioid use disorder**
- ② Formally assess the severity of opioid withdrawal (COWS)**
- ③ Assess patient willingness for buprenorphine**
- ④ Provide ED-initiated buprenorphine (ED or home induction)**
- ⑤ Overdose education and naloxone distribution (OEND)**
- ⑥ Provide formal referral for ongoing opioid agonist treatment**

 The picture can't be displayed.

Buprenorphine referral form

**How do I set up a
program?**



Local champions

Community Partners

Leadership Buy-In

Anticipate Barriers

Success Stories

Protocols

Know your Resources

Community Partners

- Is there an OTP, primary care practice, resident clinic, FQHC that will take a “warm handoff”?
 - What services do they offer?
 - Insurance?
 - Waitlist or mandatory waiting period?
- Anyone willing to run a Bridge or Transition Clinic?

Local Champions

- Administration, Faculty, Residents, Nursing...
 - How are you going to get providers waived?
 - How are you going to get waived providers to prescribe?
 - Do you need to consider other models?
- Know your allies
 - In the hospital and out
 - Social work/navigators/Health Promotions Advocates
 - Pharmacy!

Anticipate Challenges

- Buprenorphine
 - Waiver Requirements
 - Formulary/ED Pyxis
 - Insurance Prior Authorization?
 - Local pharmacy
- Patient
 - ID
 - Insurance
 - Transportation

Additional Challenges

- Anticipate resistance, particularly around ANY increased workload across all staff
 - How can you offload some of the work?
 - What motivates different key players?
 - Reducing repeat ED visits or psych holds
 - Staff safety
 - LOS
 - Patient satisfaction

3,




The picture can't be displayed.

Making Progress

- Engaging stakeholders helps change culture
- It will not happen overnight
- Perfect is the enemy of good
 - Don't wait for a perfect protocol or system!
- Make it as easy as possible for providers and patients

“This is about improving patient care”



Barriers & Myths

3,




The picture can't be displayed.

“Drug use is a moral failing”


“You are just substituting one drug for another”

“I'm just going to add more drugs to the community, they have enough”


“Patients are going to flock here if we start offering medications like Bup”


 The picture can't be displayed.

3.


 The picture can't be displayed.

3.


 The picture can't be displayed.

 The picture can't be displayed.

3,

 The picture can't be displayed.

3,

 The picture can't be displayed.

Opportunity

**Embrace science
based treatments**

**Engage emergency
practitioners**

**Change the trajectory of
the opioid epidemic**

Questions?

☞,



The picture can't be displayed.

kathryn.hawk@yale.edu

gail.donofrio@yale.edu